Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
SPONSORS MEMBERS (as of December 31, 2019) (as of December 31, 2019)â Financial support for the Forum is derived from government agencies, Forum membership includes a diverse industry sponsors, private foundations, and nonprofit associations. range of stakeholders from multiple sectors, including government, biopharmaceutical industry, biomedical research funders and Government Private Foundation sponsors, academia, foundations, Center for Drug Evaluation and Burroughs Wellcome Fund consortia, disease advocacy, and patient- Research, FDA focused groups. National Cancer Institute, NIH Nonprofit Organizations National Center for Advancing Association of American Medical Colleges Translational Sciences, NIH Critical Path Institute Robert Califf (Co-Chair) National Institute of Allergy and FasterCures Verily Life Sciences Infectious Diseases, NIH Foundation for the National Institutes Gregory Simon (Co-Chair) National Institute of Mental Health, NIH of Health Kaiser Permanente Washington Health National Institute of Neurological Friends of Cancer Research Research Institute and University of Disorders and Stroke, NIH New England Journal of Medicine Washington Office of Science Policy, NIH Christopher Austin National Center for Advancing Translational Industry Sciences, NIH AbbVie Inc. Amgen Inc. Linda Brady AstraZeneca National Institute of Mental Health, NIH Eli Lilly and Company Tanisha Carino GlaxoSmithKline FasterCures Johnson & Johnson (until October 2019) Merck & Co., Inc. Barry Coller Sanofi The Rockefeller University Takeda Pharmaceuticals Thomas Curran Childrenâs Mercy, Kansas City Richard Davey National Institute of Allergy and Infectious Diseases, NIH James Doroshow National Cancer Institute, NIH Jeffrey Drazen 22 New England Journal of Medicine
Forum Sponsorship and Membership Steven Galson Rob Scott Amgen Inc. AbbVie Inc. Carlos Garner (as of August 2019) Eli Lilly and Company Michael Severino Membership Julie Gerberding AbbVie Inc. Merck & Co., Inc. (until August 2019) Anne Heatherington Anantha Shekhar Takeda Pharmaceuticals Indiana University School of Other* Medicine 32% Biopharma Lynn Hudson 22% Critical Path Institute Ellen Sigal (until September 2019) Friends of Cancer Research Deborah Hung Lana Skirboll Academia Sanofi 23% Broad Institute of the Massachusetts Federal Institute of Technology and Harvard Amir Tamiz 23% Medical School National Institute of Neurological S. Claiborne Johnston Disorders and Stroke, NIH Dell Medical School, The University of Ann Taylor *Consortia, Foundations, Journals, Patient-Focused/ Texas at Austin AstraZeneca Disease Advocacy Organizations Esther Krofah Pamela Tenaerts FasterCures Clinical Trials Transformation (as of November 2019) Initiative Ross McKinney, Jr. John Wagner Association of American Medical Colleges Takeda Pharmaceuticals Joseph Menetski (until March 2019) Foundation for the National Institutes Joanne Waldstreicher of Health Johnson & Johnson Bernard Munos Carrie Wolinetz InnoThink Center for Research in Office of Science Policy, NIH Biomedical Innovation Alastair Wood Kelly Rose Vanderbilt University Burroughs Wellcome Fund Janet Woodcock Joseph Scheeren Center for Drug Evaluation and Critical Path Institute Research, FDA (as of October 2019) 23
